Publications

Once-Daily Roflumilast Cream 0.15% for Atopic Dermatitis: Pooled Results From INTEGUMENT-1/2 Phase 3 Trials

Reduction in Pruritus Across Indications in Phase 3 Trials of Topical Roflumilast

Investigator- and Patient-Rated Local Tolerability in Phase 3 Trials of Topical Roflumilast in Patients With Psoriasis, Seborrheic Dermatitis, and Atopic Dermatitis

Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis: Individual Patient Response From the Pooled DERMIS-1 and DERMIS-2 Phase 3 Trials

Effect Of Roflumilast Foam 0.3% On Quality of Life in Patients with Seborrheic Dermatitis: Patient-Reported Outcomes from The STRATUM Phase III Trial

Variability in Patient-Reported Impacts of Seborrheic Dermatitis: Physician-Rated Disease Severity Measures May Not Tell the Whole Story

The Impact of Seborrheic Dermatitis on Quality Of Life: A Dermatology Life Quality Index Benchmarking Analysis

Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR Trial: Efficacy, Patient-Reported Outcomes, and Safety

Safety, Efficacy, and Pharmacokinetics of Roflumilast Cream 0.3% Once Daily for Treatment of Plaque Psoriasis in Children Aged 2–11 Years

Efficacy and Safety of Roflumilast Foam 0.3% in Patients With Scalp and Body Psoriasis in the Phase 3 ARRECTOR Trial